What is Kintara Therapeutics 10-Year Sortino Ratio?
The 10-Year Sortino Ratio measures the additional return that an investor receives per unit of the downside risk over the past ten years. As of today (2025-01-18), Kintara Therapeutics's 10-Year Sortino Ratio is Not available.
Competitive Comparison of Kintara Therapeutics's 10-Year Sortino Ratio
For the Biotechnology subindustry, Kintara Therapeutics's 10-Year Sortino Ratio, along with its competitors' market caps and 10-Year Sortino Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kintara Therapeutics's 10-Year Sortino Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kintara Therapeutics's 10-Year Sortino Ratio distribution charts can be found below:
* The bar in red indicates where Kintara Therapeutics's 10-Year Sortino Ratio falls into.
Kintara Therapeutics 10-Year Sortino Ratio Calculation
The 10-Year Sortino Ratio measures the risk-adjusted return of an investment asset or portfolio in the last ten year, focusing specifically on downside risk rather than total risk. A stock / portfolio's 10-Year Sortino Ratio can be calculated by dividing the difference between the ten-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the downside risks over the past ten year.
A downside risk is a potential loss from the asset or investment. The Downside risk here is measured by the downside deviation, which is the standard deviation of negative returns.
Kintara Therapeutics (NAS:KTRA) 10-Year Sortino Ratio Explanation
The 10-Year Sortino Ratio inidicates the risk-adjusted return of an investment over the past ten year. It is calculated as the annualized result of the average ten-year monthly excess returns divided by the standard deviation of negative returns in the ten-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.
Differnt from the Sharpe Ratio that penalizes both upside and downside volatility equally, the Sortino Ratio penalizes only those returns falling below a user-specified target or required rate of return. The expected returns here is set to the risk-free rate as well.
Kintara Therapeutics 10-Year Sortino Ratio Related Terms
Thank you for viewing the detailed overview of Kintara Therapeutics's 10-Year Sortino Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
KTRA has been successfully added to your